Diversity in enoyl-acyl carrier protein reductases

R. P. Massengo-Tiassé, J. E. Cronan

Research output: Contribution to journalReview article

Abstract

The enoyl-acyl carrier protein reductase (ENR) is the last enzyme in the fatty acid elongation cycle. Unlike most enzymes in this essential pathway, ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. The primary anti-tuberculosis drug, isoniazid, and the broadly used antibacterial compound, triclosan, both target this enzyme. In this review, we discuss the diversity of ENRs, and their inhibitors in the light of current research progress.

Original languageEnglish (US)
Pages (from-to)1507-1517
Number of pages11
JournalCellular and Molecular Life Sciences
Volume66
Issue number9
DOIs
StatePublished - Jan 1 2009

Fingerprint

Acyl Carrier Protein
Oxidoreductases
Triclosan
Isoniazid
Enzymes
Tuberculosis
Research
Pharmaceutical Preparations
fatty acid elongases

Keywords

  • Enoyl-acyl carrier protein reductase
  • Fatty acid biosynthesis
  • Fatty acid synthesis II
  • Medium-chain dehydrogenase reductase
  • Shortchain dehydrogenase reductase
  • Triclosan

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Diversity in enoyl-acyl carrier protein reductases. / Massengo-Tiassé, R. P.; Cronan, J. E.

In: Cellular and Molecular Life Sciences, Vol. 66, No. 9, 01.01.2009, p. 1507-1517.

Research output: Contribution to journalReview article

Massengo-Tiassé, R. P. ; Cronan, J. E. / Diversity in enoyl-acyl carrier protein reductases. In: Cellular and Molecular Life Sciences. 2009 ; Vol. 66, No. 9. pp. 1507-1517.
@article{2cf77bb41b2c4d2ebde1eccdd0a4970f,
title = "Diversity in enoyl-acyl carrier protein reductases",
abstract = "The enoyl-acyl carrier protein reductase (ENR) is the last enzyme in the fatty acid elongation cycle. Unlike most enzymes in this essential pathway, ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. The primary anti-tuberculosis drug, isoniazid, and the broadly used antibacterial compound, triclosan, both target this enzyme. In this review, we discuss the diversity of ENRs, and their inhibitors in the light of current research progress.",
keywords = "Enoyl-acyl carrier protein reductase, Fatty acid biosynthesis, Fatty acid synthesis II, Medium-chain dehydrogenase reductase, Shortchain dehydrogenase reductase, Triclosan",
author = "Massengo-Tiass{\'e}, {R. P.} and Cronan, {J. E.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s00018-009-8704-7",
language = "English (US)",
volume = "66",
pages = "1507--1517",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "9",

}

TY - JOUR

T1 - Diversity in enoyl-acyl carrier protein reductases

AU - Massengo-Tiassé, R. P.

AU - Cronan, J. E.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The enoyl-acyl carrier protein reductase (ENR) is the last enzyme in the fatty acid elongation cycle. Unlike most enzymes in this essential pathway, ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. The primary anti-tuberculosis drug, isoniazid, and the broadly used antibacterial compound, triclosan, both target this enzyme. In this review, we discuss the diversity of ENRs, and their inhibitors in the light of current research progress.

AB - The enoyl-acyl carrier protein reductase (ENR) is the last enzyme in the fatty acid elongation cycle. Unlike most enzymes in this essential pathway, ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. The primary anti-tuberculosis drug, isoniazid, and the broadly used antibacterial compound, triclosan, both target this enzyme. In this review, we discuss the diversity of ENRs, and their inhibitors in the light of current research progress.

KW - Enoyl-acyl carrier protein reductase

KW - Fatty acid biosynthesis

KW - Fatty acid synthesis II

KW - Medium-chain dehydrogenase reductase

KW - Shortchain dehydrogenase reductase

KW - Triclosan

UR - http://www.scopus.com/inward/record.url?scp=67649537863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649537863&partnerID=8YFLogxK

U2 - 10.1007/s00018-009-8704-7

DO - 10.1007/s00018-009-8704-7

M3 - Review article

C2 - 19151923

AN - SCOPUS:67649537863

VL - 66

SP - 1507

EP - 1517

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 9

ER -